Acne and Rosacea Treatments Linked to Cancer Risk Due to Benzene Contamination

Improper storage of benzoyl peroxide products may lead to the formation of carcinogenic benzene, posing a public health concern.

Benzoyl peroxide (BPO) in acne and rosacea treatments can degrade into benzene, a known carcinogen, when stored at room temperature or exposed to UV light.
A study found that 34% of tested BPO products exceeded the FDA's benzene limit of 2 parts per million, with some reaching as high as 35.3 ppm.
Cold storage significantly reduces the formation of benzene, suggesting refrigeration as a temporary solution to minimize exposure.
Encapsulation techniques do not prevent benzene formation, highlighting the need for improved formulations and regulatory measures.
Further research is necessary to establish a direct link between BPO product use and cancer risk, with calls for industry and regulatory actions to ensure safety.